| Drug Name |
Fluorouracil |
| Drug ID |
BADD_D00931 |
| Description |
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. |
| Indications and Usage |
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
L01BC02 |
| DrugBank ID |
DB00544
|
| KEGG ID |
D00584
|
| MeSH ID |
D005472
|
| PubChem ID |
3385
|
| TTD Drug ID |
D05LEO
|
| NDC Product Code |
63323-117; 0378-8078; 51672-4062; 16714-178; 70700-189; 51862-362; 51672-4118; 70700-186; 50090-4264; 38779-0025; 51672-4063; 0378-4791; 68001-524; 25021-215; 68001-266; 62049-185; 38779-3185; 16729-276; 68001-525; 0187-3204; 68083-269; 68083-293; 51927-1085; 68083-270; 66530-249; 28105-421; 16110-812; 68083-292; 70700-187; 0187-5200; 70700-188; 59348-0055; 12070-0002; 49452-3175; 16729-542; 0395-8080; 62991-1486 |
| Synonyms |
Fluorouracil | 5FU | 5-FU | 5-Fluorouracil | 5 Fluorouracil | Fluoruracil | 5-FU Lederle | 5 FU Lederle | 5-FU Medac | 5 FU Medac | 5-HU Hexal | 5 HU Hexal | Adrucil | Carac | Efudix | Fluoro-Uracile ICN | Fluoro Uracile ICN | Efudex | Fluoroplex | Flurodex | Fluorouracil Mononitrate | Fluorouracil Monopotassium Salt | Fluorouracil Monosodium Salt | Fluorouracil Potassium Salt | Fluorouracil-GRY | Fluorouracil GRY | Fluorouracile Dakota | Dakota, Fluorouracile | Fluorouracilo Ferrer Far | Fluracedyl | Haemato-FU | Haemato FU | Neofluor | Onkofluor | Ribofluor | 5-Fluorouracil-Biosyn | 5 Fluorouracil Biosyn |
